Phase 1 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have an advanced solid tumor (a cancer that has spread or cannot be removed)
- Your cancer can be measured on scans, following standard measurement guidelines called RECIST v1.1
- You are generally able to carry out daily activities with little or no limitation (confirm with trial site, as this is assessed using a specific medical scale called ECOG 0-1)
- Your major organs (such as kidneys, liver, and blood cells) are functioning well enough, based on lab tests
Who may not be able to join:
- You are still experiencing significant side effects from a previous cancer treatment that have not yet improved to a mild or resolved level (minor hair loss or certain lab value changes may be exceptions — confirm with trial site)
- You have received certain cancer treatments — including chemotherapy, experimental therapies, or other cancer medicines — too recently before starting this trial (within the last 14 days for tablet/pill-type medicines, or 28 days for biological therapies)
- Your cancer has spread to the brain and is getting worse or causing symptoms
- You have a serious uncontrolled medical condition, a major non-cancer illness, or an active uncontrolled infection
- You have a significant history of heart disease
- You have a history of certain blood or bone marrow disorders called MDS or AML
- You have had another type of cancer within the past 3 years, with some exceptions such as certain treated skin cancers, early-stage breast cancer (DCIS), or low-risk prostate cancer (confirm with trial site)
- You are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Caroline Labib, PharmD, TORL Biotherapeutics, LLC
Phone: 310-348-9636
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of adverse events and serious adverse events; Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.